Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics received an extension from Nasdaq until December 28, 2026, to regain compliance with the minimum $1.00 bid price requirement, following its transfer to the Nasdaq Capital Market. The company is actively monitoring its stock price and considering options, including a reverse stock split, to avoid delisting. Additionally, the company held its 2026 Annual General Meeting where all matters were approved, including the re-election of directors and the re-appointment of auditors, with no dividend recommended for fiscal year 2025.

Barinthus Biotherapeutics plc has filed a definitive proxy statement (DEF 14A) announcing its 2026 Annual General Meeting (AGM) to be held on July 2, 2026. Key agenda items include the re-election of directors Karen T. Dawes and Anne M. Phillips, the re-appointment and ratification of PricewaterhouseCoopers LLP as auditors, and the receipt and advisory approval of financial reports and director compensation. The meeting will take place in London, with options for both ordinary shareholders and ADS holders to vote.

Barinthus Biotherapeutics plc reported a net loss of $(5.5) million for Q1 2026, a significant improvement from $(19.7) million in Q1 2025. The company also provided updates on its merger agreement with Clywedog Therapeutics, Inc., where Barinthus will become a wholly-owned subsidiary of Topco, and Clywedog will merge into Topco. Barinthus shareholders will receive Topco common stock, and a potential $27.0 million self-tender offer for Topco shares may precede the merger.

Barinthus Bio reported a Q1 2026 net loss of $(5.5) million, a significant improvement from $(19.6) million in Q1 2025. The company announced that its proposed combination with Clywedog Therapeutics Inc. is progressing towards a mid-2026 closing, aiming to create a differentiated company focused on metabolic and autoimmune diseases with an estimated cash runway through 2027. Additionally, Doug Swirsky was appointed CFO, effective May 1, 2026, and Phase 1 AVALON trial data for VTP-1000 in celiac disease is expected in H2 2026.

Barinthus Biotherapeutics plc. announced the appointment of Douglas Swirsky as its new Chief Financial Officer and principal accounting officer. The appointment is effective May 1, 2026. Mr. Swirsky has over 25 years of experience, including prior roles as CFO of MaxCyte, Inc. and AavantiBio, Inc., and as President and CEO of Rexahn Pharmaceuticals, Inc. He also serves as chairman of the board for Cellectar Biosciences, Inc.